egt-1442

Bexagliflozin (also known as EGT1442) is a potent and selective SGLT2 inhibitor that effectively reduces blood glucose and HbA(1c) levels in db db mice while increasing the survival time of stroke-prone rats. The IC(50) values of EGT1442 for human SGLT1 and SGLT2 are 5.6 μM and 2 nM, respectively. In studies involving normal rats and dogs, EGT1442 induces saturated urinary glucose excretion with ED(50) values of 0.38 mg kg and 0.09 mg kg, respectively. Additionally, EGT1442 exhibits favorable properties in both in vivo and in vitro studies, indicating its potential positive impact on the management of type 2 diabetes.

Bexagliflozin (EGT1442) is a potent, selective sodium glucose co-transporter 2 (SGLT2) inhibitor with IC50 values of 2 nM for human SGLT2 and 5.6 μM for human SGLT1.